Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navigational Bronchoscopy PDT with Photofrin for Peripheral Lung Tumors
NCT02916745Phase 1Completed
- Sponsor
- Concordia Laboratories
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of porfimer sodium in non-small cell lung cancer (NSCLC) and cancer, sponsored by Concordia Laboratories. Primary endpoints: Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor at Day 3 and Adverse Events Incidence Indicating Safety of Navigational Bronchoscopy-interstitial-Photodynamic Therapy (i-PDT) up to 6 months. Started Jan 2017; status: completed.
02
Drugs
porfimer sodium
03
Conditions
non-small cell lung cancer (NSCLC)cancer
Beyond the preview
Go deeper on NCT02916745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916745.